Marker Therapeutics
MRKR
5 hedge funds and large institutions have $119K invested in Marker Therapeutics in 2016 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.38% more ownership
Funds ownership: 0% → 0.38% (+0.38%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$115K |
| 2 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$31.6K |
| 3 |
AG
Advisor Group
Phoenix,
Arizona
|
+$1.3K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
+$372 |
| 5 |
Morgan Stanley
New York
|
+$47 |
Top Sellers
MRKR Hedge Fund Activity: Q4 2016 in Review
5 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q4 2016, worth a combined $119K.
Buyers outnumbered sellers: 5 funds opened new MRKR positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $115K.
- 5 institutional investors held Marker Therapeutics (MRKR) as of Q4 2016, up from 0 in Q3 2016.
- Funds reported $119K of Marker Therapeutics stock for Q4 2016.
- 5 funds opened new Marker Therapeutics positions in Q4 2016 and 0 closed out, a net change of +5 holders.
- The largest Marker Therapeutics buyer in Q4 2016 was Millennium Management, an estimated $115K added.
Based on aggregated 13F filings for Q4 2016.